Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma |
NCT06399835: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis |
|
|
| Recruiting | 4 | 120 | RoW | Enavogliflozin, Envlo Tab., Pioglitazone, Actos Tab. | Seoul National University Bundang Hospital, Daewoong Pharmaceutical Co. LTD. | Type 2 Diabetes | 06/26 | 12/26 | | |
| Not yet recruiting | 4 | 154 | RoW | SGLT2 inhibitor, SGLT2 inhibitor: Enavogliflozin (Brand names: Envlo tab) | Samsung Medical Center | Heart Failure, Preserved Ejection Fraction | 12/25 | 06/26 | | |
ARNI-TAVI, NCT05672836: ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement |
|
|
| Not yet recruiting | 4 | 1040 | RoW | Enavogliflozin, Standard-of-Care, Standard-of-Care medical therapy | Duk-Woo Park, MD, CardioVascular Research Foundation, Korea, Daewoong Pharmaceutical Co. LTD. | Aortic Valve Stenosis | 12/25 | 04/26 | | |
NCT06141980: Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 134 | NA | DWP16001 0.3 mg | Daewoong Pharmaceutical Co. LTD. | T2DM (Type 2 Diabetes Mellitus) | 09/25 | 09/25 | | |
NCT05505994: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin |
|
|
| Active, not recruiting | 3 | 340 | RoW | DWP16001, DWP16001 tablet, Dapagliflozin, Dapagliflozin tablet, DWP16001 Placebo, DWP16001 Placebo tablet, Dapagliflozin Placebo, Dapagliflozin Placebo tablet | Daewoong Pharmaceutical Co. LTD. | Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 02/24 | 09/24 | | |
ENHANCE-I, NCT05466643: A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 240 | RoW | DWP16001 0.3mg, DWP16001 Placebo | Daewoong Pharmaceutical Co. LTD. | Type 2 Diabetes Mellitus | 09/24 | 09/24 | | |
| Recruiting | 3 | 540 | RoW | Enavogliflozin, Envlo (brand name), Placebo | Asan Medical Center, Daewoong Pharmaceutical Co. LTD. | Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction | 04/26 | 10/27 | | |
NCT05207176: Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities |
|
|
| Not yet recruiting | 1 | 24 | NA | DWP16001 | Daewoong Pharmaceutical Co. LTD. | Healthy | 04/22 | 08/22 | | |
NCT05321732: The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults |
|
|
| Enrolling by invitation | 1 | 24 | RoW | DWP16001, DWP202010 | Daewoong Pharmaceutical Co. LTD. | Healthy Volunteers | 08/22 | 08/22 | | |
NCT05500898: Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults |
|
|
| Not yet recruiting | 1 | 53 | NA | DWP16001, DWC202204+DWC202205, DWP16001+DWC202204+DWC202205 | Daewoong Pharmaceutical Co. LTD. | Healthy | 10/22 | 02/23 | | |
NCT05737771: To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination |
|
|
| Recruiting | 1 | 40 | RoW | DWC202213, DWJ1563, DWP16001 | Daewoong Pharmaceutical Co. LTD. | FDC, Diabetes Mellitus, Type 2 | 03/23 | 06/23 | | |
NCT05797922: To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers |
|
|
| Recruiting | 1 | 32 | RoW | DWP16001, DWP16001 0.3mg | Daewoong Pharmaceutical Co. LTD. | Healthy | 05/23 | 11/23 | | |
NCT05747664: To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function |
|
|
| Recruiting | 1 | 24 | RoW | DWP16001, DWP16001 0.3mg | Daewoong Pharmaceutical Co. LTD. | Diabetes Mellitus, Type 2 | 04/24 | 04/24 | | |
NCT06427083: Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | N/A | 240 | NA | Envlo Tablet, Envolomet SR Tablet | Daewoong Pharmaceutical Co. LTD. | Type 2 Diabetes Mellitus | 12/25 | 06/26 | | |
NCT05926414: To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus |
|
|
| Recruiting | N/A | 15000 | RoW | Enavogliflozin, Envlo Tablet, Envlomet SR Tablet | Daewoong Pharmaceutical Co. LTD. | Diabetes Mellitus, Type 2 | 12/24 | 06/25 | | |